March 26th, 2012
Bariatric Surgery Turns Back the Clock on Diabetes
Larry Husten, PHD
Two new randomized trials offer evidence that bariatric surgery is highly effective in obese patients with diabetes. The results, according to Paul Zimmet and K. George M.M. Alberti, writing in an editorial in the New England Journal of Medicine, “are likely to have a major effect on future diabetes treatment.”
In the STAMPEDE trial, which was presented at the American College of Cardiology and published simultaneously in the New England Journal of Medicine, 150 obese patients with uncontrolled type 2 diabetes were randomized to medical therapy alone or medical therapy plus either Roux-en-Y gastric bypass or sleeve gastrectomy. Philip Schauer presented the main results.
Percentages of patients with glycated hemoglobin level of 6% or less at 1 year:
- medical: 12%
- gastric bypass: 42%
- sleeve gastrectomy: 37%
Mean glycated hemoglobin at 1 year:
- medical: 7.5
- gastric bypass: 6.4
- sleeve gastrectomy: 6.6
Weight loss at 1 year:
- medical: -5.4 kg
- gastric bypass: -29.4 kg
- sleeve gastrectomy -25.1 kg
Patients in the medical-therapy group increased their use of diabetes medications, whereas the surgical patients significantly dropped their use of these drugs. Some 38% of medical-therapy patients used insulin compared with only 4% and 8% in the gastric-bypass and sleeve-gastrectomy groups, respectively.
The authors concluded that “bariatric surgery represents a potentially useful strategy for management of uncontrolled diabetes, since it has been shown to eliminate the need for diabetes medications in some patients and to markedly reduce the need for drug treatment in others.”
In a second study, also published in the New England Journal of Medicine, bariatric surgery was also found to be highly effective for diabetic subjects. Sixty obese patients with diabetes were randomized to bariatric surgery (Roux-en-Y gastric bypass or biliopancreatic diversion) or conventional medical therapy.
Diabetes remission at 2 years:
- medical therapy: 0%
- gastric bypass: 75%
- biliopancreatic diversion: 95%
In their editorial, Zimmet and Alberti wrote that one important implication of the studies is that bariatric surgery should perhaps “not be seen as a last resort.” For some obese patients with diabetes, surgery “might well be considered earlier in the treatment.”
Categories: General, Prevention
Tags: bariatric surgery, diabetes, obesity, weight loss
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
3 Responses to “Bariatric Surgery Turns Back the Clock on Diabetes”
-
Search the Archive
Archives by Date
NEJM — Recent Cardiology Articles- Extended Outcomes of the ADAPT AF-DES Trial November 19, 2026In patients with atrial fibrillation and a stent placed at least 1 year earlier, non–vitamin K antagonist oral anticoagulant monotherapy resulted in fewer net adverse clinical events at 2 years than a NOAC plus clopidogrel.
- Aspirin Omission at the Time of Primary Percutaneous Coronary Intervention in STEMI November 19, 2026Among patients with STEMI, prasugrel monotherapy initiated before PCI was not noninferior to dual antiplatelet therapy with prasugrel plus aspirin for a composite of death, stroke, or myocardial infarction at 12 months.
- Expanding the Evidence and Indications for Thrombectomy in Ischemic Stroke November 19, 2026In 2015, pivotal randomized, controlled trials established the benefit of endovascular treatment for acute ischemic stroke due to a large-vessel occlusion.1,2 The trials showed a major clinical benefit in patients presenting with relatively standard stroke features: large-vessel occlusion in the anterior circulation; relevant clinical neurologic deficit; short time...
- Too Soon to Say Goodbye — Aspirin at the Door in STEMI November 19, 2026The 19th-century English biologist Thomas H. Huxley once said, “The great tragedy of Science — the slaying of a beautiful hypothesis by an ugly fact.” For as long as many can recall, aspirin has been the first drug administered for the treatment of ST-segment elevation myocardial infarction (STEMI), often in...
- Mechanical Thrombectomy 24 to 72 Hours after Large-Vessel Ischemic Stroke November 19, 2026Among patients with salvageable tissue 24 to 72 hours after stroke, physical function at 90 days was better with thrombectomy than with medical care alone, but intracerebral hemorrhage and death were more common with thrombectomy.
- Extended Outcomes of the ADAPT AF-DES Trial November 19, 2026
-
Tag Cloud
- ACS AF AHA anticoagulation aortic valve replacement apixaban aspirin atrial fibrillation CABG cardiovascular risk cholesterol clopidogrel dabigatran diabetes diet drug-eluting stents epidemiology ESC exercise FDA FDA approvals Fellowship training guidelines HDL heart failure hypertension ICDs MI myocardial infarction obesity PCI Primary PCI risk factors rivaroxaban statins STEMI stents stroke stroke prevention TAVI TAVR type 2 diabetes venous thromboembolism warfarin women

Impressive short-term results. But, before incorporating this treatment in the standard guidelines, we will have to wait for not only the long-term side-effects,but also the durability of glycemic control, given the progressive nature of beta-cell dysfunction. After all, this is a truly “By-pass” procedure & not addressing the basic pathophysiology of diabetes.
Has anyone compared the gastric bypass &/or sleeve gastrectomy with a medical control group that lost a similar amount of weight (as on a VLCD)and similar exercise regimen? What is the purported mechanism or is it simply weight loss and exercise?
A comparative effectiveness review on this subject is being prepared by the Agency for Healthcare Research and Quality’s Effective Healthcare Program. Should be out later this year.